Equities analysts predict that China Biologic Products Holdings Inc (NASDAQ:CBPO) will announce earnings per share of $0.70 for the current quarter, according to Zacks. Zero analysts have issued estimates for China Biologic Products’ earnings. China Biologic Products reported earnings of $0.76 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 7.9%. The firm is expected to report its next earnings results on Wednesday, March 4th.
On average, analysts expect that China Biologic Products will report full-year earnings of $3.94 per share for the current fiscal year. For the next fiscal year, analysts expect that the firm will report earnings of $4.45 per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover China Biologic Products.
China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings data on Wednesday, November 13th. The biopharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.52. China Biologic Products had a net margin of 31.22% and a return on equity of 9.79%. The firm had revenue of $136.10 million for the quarter. During the same quarter in the previous year, the business earned $0.96 EPS. The company’s quarterly revenue was up 14.3% on a year-over-year basis.
Several research firms recently weighed in on CBPO. ValuEngine raised shares of China Biologic Products from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. BidaskClub cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Finally, Zacks Investment Research cut shares of China Biologic Products from a “buy” rating to a “hold” rating in a research note on Thursday, October 24th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. China Biologic Products currently has an average rating of “Hold” and a consensus target price of $92.67.
A number of institutional investors have recently made changes to their positions in CBPO. Bank of New York Mellon Corp boosted its position in shares of China Biologic Products by 2.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 17,276 shares of the biopharmaceutical company’s stock valued at $1,647,000 after acquiring an additional 357 shares during the last quarter. Tower Research Capital LLC TRC increased its position in China Biologic Products by 446.9% in the second quarter. Tower Research Capital LLC TRC now owns 1,761 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 1,439 shares during the last quarter. SG Americas Securities LLC purchased a new stake in China Biologic Products during the second quarter valued at $187,000. Paradice Investment Management LLC purchased a new stake in China Biologic Products during the second quarter valued at $373,000. Finally, Jane Street Group LLC purchased a new stake in China Biologic Products during the second quarter valued at $486,000. 38.66% of the stock is owned by institutional investors.
Shares of NASDAQ:CBPO traded down $0.40 during midday trading on Thursday, reaching $116.61. 68,749 shares of the company were exchanged, compared to its average volume of 171,375. The business’s fifty day moving average is $115.79 and its two-hundred day moving average is $102.98. China Biologic Products has a one year low of $70.30 and a one year high of $119.44. The stock has a market cap of $4.61 billion, a PE ratio of 29.01, a price-to-earnings-growth ratio of 7.09 and a beta of 1.15.
About China Biologic Products
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
See Also: Municipal Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.